linjc16/ctgov huggingface dataset:
High Risk Breast Cancer Screening Program

Study Overview
=================
Brief Summary
-----------------
Objectives: To screen population with high risk for breast cancer To promote the concept and importance of surveillance mammography To find out the incidence of breast cancer in population who are in high risk for breast cancer To collect blood samples for molecular analysis

Official Title
-----------------
High Risk Breast Cancer Screening Program

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female > 40 years of age Women who have first-degree relative suffered from breast cancer Women who have first-degree relative suffered from ovarian cancer Family history of male breast cancer Family history of breast cancer (not necessarily first degree relatives) diagnosed before age of 40 Family history of breast cancer (not necessarily first degree relatives) affecting 2 or more family members Personal history of ovarian cancer Personal history of premalignant conditions of breast and ovary Exclusion Criteria: Women with mammogram within one year

Ages Eligible for Study
-----------------
Minimum Age: 41 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hereditary Breast Cancer (BRCA1, BRCA2)
Liver Fibrosis Evaluation Using Ultrasound Shear Wave Imaging

Study Overview
=================
Brief Summary
-----------------
The Researchers are trying to assess the effectiveness of a new ultrasound technique for non-invasive evaluation of liver fibrosis.

Detailed Description
-----------------
Utilizing vibrating transducer, receiver and speaker in differing sequences, while collecting ultrasound liver tissue elastography measurements during participant breath holds. Participants fast for a minimum of four hours and are positioned lying on left side with knees slightly bent.

Official Title
-----------------
Liver Fibrosis Evaluation Using Ultrasound Shear Wave Imaging

Conditions
-----------------
Liver Fibrosis

Intervention / Treatment
-----------------
* Device: Mechanical Vibrations with Ultrasound Shear Wave Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers or patients who are scheduled for clinically indicated liver MRE for fibrosis staging. Age 18 to 80. Exclusion Criteria: Subjects lacking capacity to consent Subjects with unreliable ultrasound or MRE measurements. Pregnant women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mechanical Vibrations with Ultrasound Shear Wave Imaging<br>Subjects that are scheduled to undergo a clinical indicated Magnetic Resonance Elastography (MRE) will also have mechanical vibrations ultrasound shear wave imaging to measure liver stiffness | Device: Mechanical Vibrations with Ultrasound Shear Wave Imaging<br>* Multiple miniature mechanical vibrators will be placed on the body surface of rib cage of the subject or introduced through an audio loudspeaker in contact with the subject's upper torso or through miniature vibrator attached to the ultrasound probe. Repeated ultrasound stiffness measurements will be made at different locations within the liver parenchyma while the mini vibrators introduce shear wave in the liver, similar to an MRE examination.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Liver Stiffness Measured by MRE | Liver stiffness measured by standard of care Magnetic Resonance Elastography reported in Kilopascals (kPa) (used as a benchmark reference in this study). | Baseline, approximately 1 day | 
| Liver Stiffness Measured by Mechanical Vibrations With Ultrasound Shear Wave Imaging | Liver stiffness measured by Mechanical Vibrations with Ultrasound Shear Wave Imaging reported in kilopascal (kPa). | Baseline, approximately 1 day |
Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease

Study Overview
=================
Brief Summary
-----------------
The aim of this therapeutic trial is to compare the response of subjects with active IBD to daily intravenous dexamethasone versus the response to daily intravenous methylprednisolone.

Official Title
-----------------
Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease

Conditions
-----------------
Inflammatory Bowel Disease (IBD)

Intervention / Treatment
-----------------
* Drug: Dexamethasone
* Drug: Methylprednisolone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parental informed consent Subjects 6 to 19 years of age with confirmed diagnosis of IBD (Crohn's disease, ulcerative colitis or indeterminate colitis), who on admission to the hospital have a PCDAI>15 or a Clinical-Activity Index for the Evaluation of Patients with Ulcerative Colitis of >10. Infectious causes (viruses, bacteria, parasites) have been ruled out. Exclusion Criteria: Subjects in which the administration of corticosteroids would be contraindicated such as systemic or enteric infections diagnosed by stool analysis including culture, Clostridium Difficile toxin assay, rotavirus or adenovirus 40/41 antigens. Subjects with enterostomy or colostomy Subjects with one or more of the following conditions: unstable vital signs, acute abdomen, toxic megacolon, intestinal obstruction, intestinal perforation

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Dexamethasone|nan|
|Drug: Methylprednisolone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pediatric Crohn's Disease Activity Index (PCDAI) |  |  | 
| Clinical-Activity Index for the Evaluation of Patients with Ulcerative Colitis |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Partial Harvey Bradshaw score (pHB) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Inflammatory Bowel Disease (IBD)
Glutaminergic Agents for Cocaine Abuse - 5

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate glutaminergic agents for cocaine abuse.

Official Title
-----------------
Glutaminergic Agents for Cocaine Abuse

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Nimodipine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nimodipine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cocaine effects |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cocaine
Sleep at 30 Degrees in Glaucoma

Study Overview
=================
Brief Summary
-----------------
This study is designed to investigate the effect of body posture (particularly when sleeping) on the pressure in the eye. The effect of body posture on progressive glaucoma (glaucoma where a significant change i.e. a disc hemorrhage has occurred) is not known. The study will involve being admitted to the Sleep Unit of the University Health Network at Toronto Western Hospital for 1 night (14 hours). IOP will be measured in both eyes every 2 hours with a Tonopen, along with brachial blood pressure (BP), in the sitting position until the patients reach their normal sleep cycle time. Patients will then be asked to sleep in either lying down or reclining at a 30 degrees position and have the IOP measurements and brachial BP every 2 hours in that position. The same cohort of patients will then be invited for a repeat 14 hour IOP and BP measurement but will change their position, i.e. sitting before will now be supine and vice versa.

Conditions
-----------------
Glaucoma

Intervention / Treatment
-----------------
* Behavioral: Sleeping position in glaucoma patient


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: This pilot study included patients with progressive NTG or POAG as evidenced by disc hemorrhage despite well controlled Intraocular pressures (IOP), who were able to sleep flat Exclusion Criteria: Any patients who were not able to sign a consent or lying flat during sleep

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Sleeping position in glaucoma patient|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
progressive glaucoma despite controlled IOP
Observational Study in Patients Who Underwent an Haploidentical Transplantation With T-repleted Bone Marrow

Study Overview
=================
Brief Summary
-----------------
Outcome evaluation in patients who underwent transplantation with T-repleted bone marrow after post-transplantation cyclophosphamide

Detailed Description
-----------------
Patients who underwent transplantation with T-repleted bone marrow haploidentical transplantation will be analyzed considering toxicity incidence (GVHD, infective complications, graft-failure incidence and TRM)and efficacy variables (Overall Survival, Progression Free Survival and Relapse incidence)

Official Title
-----------------
Retrospective-prospective Observational Study for Data Collection of Patients Who Underwent an Haploidentical Transplantation After Non-myeloablative Conditioning Regimen

Conditions
-----------------
Hematologic Malignancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - patients affected by hematologic neoplasia who underwent a haploidentical transplantation (2-3 mismatches) from a familiar donor, with non-ex vivo manipulated bone marrow and post-transplantation cyclophosphamide Exclusion Criteria: ex vivo manipulated bone marrow transplantation use of antilymphocyte serum during conditioning

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| transplanted patients<br>T-repleted haploidentical transplanted patients in Italy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| toxicity evaluation | Chronic and acute GVHD, infectious complications, graft failure, TRM | 1 year |
Percutaneous Transhepatic Intrahepatic Portosystemic Shunt for Treatment of Portal Vein Occlusion With Symptomatic Portal Hypertension After Splenectomy

Study Overview
=================
Brief Summary
-----------------
To evaluate the values of percutaneous transhepatic intrahepatic portosystemic shunt for treatment of portal vein occlusion with symptomatic portal hypertension after splenectomy.

Conditions
-----------------
Hypertension, Portal, Portal Vein, Cavernous Transformation Of

Intervention / Treatment
-----------------
* Procedure: Percutaneous transhepatic intrahepatic portosystemic shunt


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with portal hypertension who have the history of splenectomy and have enough image information to confirm occlusion of portal vein Exclusion Criteria: Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Shunt<br>Perform percutaneous transhepatic intrahepatic portosystemic shunt | Procedure: Percutaneous transhepatic intrahepatic portosystemic shunt<br>* Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| No gastrointestinal rebleeding in 1 month after interventions | No gastrointestinal rebleeding in 1 month after interventions | 1 month | 
| Ascites disappear in 1 month after interventions | Ascites disappear in 1 month after interventions | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Whether the shunt is patent after interventions in 6 months | Patent shunt in 6 months after interventions proved by US or CT | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Portal, Portal Vein, Cavernous Transformation Of, Portosystemic shunt, Radiology, Interventional
Minimally Invasive Holmium:YAG Laser Blepharoplasty

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to is to evaluate the safety and effectiveness of the FDA approved Holmium:YAG laser for reducing lower eyelid bags.

Detailed Description
-----------------
The researchers are interested in learning if the more precise Holmium:YAG laser can effectively tighten the orbital septum, a barrier of the orbit which holds fat in the bony orbit, while resulting in less unintentional surrounding damage and side effects.

Official Title
-----------------
Minimally Invasive Holmium:YAG Laser Blepharoplasty

Conditions
-----------------
Lower Eyelid Entropion

Intervention / Treatment
-----------------
* Procedure: Holmium: YAG laser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male/female 30 years and older have pronounced lower eyelid fat pads. Exclusion Criteria: based on medical problems. Previous surgery or trauma to lower eyelid or orbit. pregnant or lactating.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Holmium: YAG laser<br>Subjects will go under minimally invasive Holmium: YAG laser blepharoplasty | Procedure: Holmium: YAG laser<br>* Minimally Invasive Holmium:YAG laser Blepharoplasty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Lower Eyelid Bags. | Preoperative and postoperative (postoperative visits were at day 1, 1 week, 1 month, and 2 months) .photographs were evaluated by 6 surgeons on a 5-point Likert scale which 1 indicates worsening, 2 means unchanged, 3 is mild improvement, 4 is moderate improvement, and 5 indicates complete correction. | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
eyelid fat pads
Usage of Tramadol With Levobupivacaine for Pain Treatment After Cesarean Section

Study Overview
=================
Brief Summary
-----------------
Patients experience considerable amount of pain after cesarean section. The aim of this study is to investigate the effect of tramadol (an opioid pain killer) added to levobupivacaine (a local anesthetic) in continuous wound infusion (which is done by placing a catheter in the incision) after cesarean sections.

Official Title
-----------------
The Effect of Addition of Tramadol to Levobupivacaine in Continuous Wound Infusion for Postoperative Pain Treatment in Cesarean Section

Conditions
-----------------
Pain, Postoperative

Intervention / Treatment
-----------------
* Drug: Tramadol infusion via wound catheter
* Drug: Levobupivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Planned cesarean section American Society of Anesthesiologists Class I-II Exclusion Criteria: Patients refusing to enroll in the study Serious coagulopathy Serious systemic disease Story of allergy to drugs being used in the study Morbid obesity (Body mass index > 30)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tramadol 1<br>1 mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion | Drug: Tramadol infusion via wound catheter<br> <br> Drug: Levobupivacaine<br> <br> |
| Experimental: Tramadol 2<br>2mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion | Drug: Tramadol infusion via wound catheter<br> <br> Drug: Levobupivacaine<br> <br> |
| Placebo Comparator: Levobupivacaine<br>0.25% levobupivacaine 4ml/h infusion | Drug: Levobupivacaine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lowering of pain as measured by visual analogue scores |  | forty eight hours after the operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| total additional analgesic consumption |  | forty eight hours after the operation |
Pharmacy Education During Covid-19 Outbreak

Study Overview
=================
Brief Summary
-----------------
Coronavirus disease 2019 (COVID-19) outbreak is considered one of the most important public health crisis all over the world. General recommendations and rules around the world have been legislated to avoid or delay transmission of covid-19. Education process and learning plan are changed to focus on online Learning instead of traditional educational model. Pharmacy is one of the important practical medical science which affected by Covid-19 outbreak.

Detailed Description
-----------------
Detailed Description: The survey will enroll as many individuals of the Egyptian pharmacy students as possible in the survey portion of the study - The number of participates have no limitations, at least 100 participants. The survey will be enrolled in online google form, face to face interview(this will be reduced to encourage social isolation) & semi-structured telephone interviews if possible. The research procedures: An online survey link will include questions regarding the effect of COVID 19 pandemic on the educational process in Egypt,and how the online learning process are affecting pharmacy students it will measure the impact on the psychological health of the students as well as their level of understanding of information.and their overall satisfaction from the e learning method of education used during the COVID 19 pandemic Face to face and semi-structured interviews if possible: For those Egyptian citizens who state that they would like to participate in an interview, a random sample will be contacted. Inclusion Criteria: pharmacy students Exclusion Criteria: non pharmacy students

Official Title
-----------------
Impact of Covid-19 on Pharmacist Student Education in Egypt

Conditions
-----------------
Event, Life Change

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pharmacy students Exclusion Criteria: non pharmacy students

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of Covid-19 on pharmacy Education study in Egypt | a survey will measure the effect of the COVID 19 pandemic on the educational process in Egypt,and how the online learning process are affecting pjarmacy students.It also measures how the change in the educational process affected the psychological health of the students as well as their level of understanding of information.and their overall satisfaction from the e learning method of education used during the COVID 19 pandemic | 12 months |